The Medical News

The Medical News

While the American Thoracic Society appreciates that the FDA took action on certain flavored cartridge-based vaping products, it is disappointed that the Administration chose to not follow through on its September 2019 promise to clear the market of all flavored electronic nicotine delivery projects. The fact that youth e-cigarette use grew by nearly 40 percent in one year should make preventing children from being able to access all vaping products an immediate priority. We continue to urge Congress to pass legislation that bans all e-cigarette flavors, including menthol for all e-cigarette products and not just pod cartridges. It is amazing how in a few short weeks, the FDA went from 'clearing the market of all flavored products' to effectively clearing the market for Juul's menthol e-cigarettes and flavored e-liquids for 'tank' vaping systems." Michelle Eakin, PhD., ATS Tobacco Action Committee Chair This policy will also allow flavorings to continue to be on the market for non-pod devices which will result in thousands of kid-friendly e-liquids to continue to be available. While there is substantial evidence that e-cigarette flavorings are linked to higher rates of initiation and transition to daily use, there is no credible evidence demonstrating flavorings help adults quit tobacco product use. Overall, this policy will not stop the youth e-cigarette epidemic. "I will leave it to others to speculate why the FDA has so quickly changed its mind," said Dr. Eakin. "Regardless, leaving menthol e-cigs on the market is good for the vaping industry and bad for kids." Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More